Noradrenaline or Dopamine in Cardiogenic Shock - A Literature Review

Q: What are the key findings of this study?

Noradrenaline is associated with better safety and clinical outcomes compared with dopamine in patients with cardiogenic shock, particularly with a lower risk of arrhythmic complications.

Q: What is the clinical evidence from this study?

Study design: Review. Population: Cardiogenic shock (n=1310). Intervention: Noradrenaline vs. Dopamine.

Q: What does this research mean for the field?

Noradrenaline is the preferred first-line vasopressor over dopamine in cardiogenic shock because dopamine is associated with an increased risk of cardiac arrhythmias. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Antoni Liebert; Katarzyna Mazurek; Anna Dominiczak; Marta Brzęcka; Stanisław Rogiński; Karol Jan Krupiniewicz; Marek Wojciechowicz; Miłosz Jan Rogiński; Mariusz Suchcicki; Łukasz Chojnowski

doi:10.31435/ijitss.3(51).2026.4927

September 24, 2026International Journal of Innovative Technologies in Social ScienceOpen Access

Noradrenaline or Dopamine in Cardiogenic Shock - A Literature Review

View Full Paper

Ask AI

Bookmark

Share

Key result

Noradrenaline is linked to better outcomes and fewer arrhythmias than dopamine in cardiogenic shock.

n=1,310

Why the study?

Choosing the most effective medication for treating cardiogenic shock remains a major clinical challenge.

Does noradrenaline improve mortality and reduce arrhythmias compared to dopamine in patients with cardiogenic shock?

Key Points

To evaluate and compare the efficacy, hemodynamic outcomes, and safety profile of noradrenaline versus dopamine in patients presenting with cardiogenic shock.
Literature searches were conducted across PubMed, Google Scholar, and the National Library of Medicine using targeted keywords.
Three studies encompassing 1,310 total patients were analyzed: one retrospective cohort study (n=520), one meta-analysis of nine randomized clinical trials (n=510), and one multicenter randomized trial subgroup analysis (n=280).
A meta-analysis of 510 patients demonstrated significantly reduced mortality with noradrenaline compared to dopamine (P < .001), alongside decreased risks of arrhythmic events (RR 3.426, 95% CI 2.120–5.510, P < .001) and gastrointestinal reactions (RR 5.474, 95% CI 2.917–10.273, P < .001).
In a randomized trial subgroup of 280 patients, dopamine was associated with a significantly higher mortality rate (p=0.03) and increased risk of arrhythmic events (P < 0.001) compared with noradrenaline.
In a retrospective study of 520 patients, fewer patients receiving noradrenaline required an additional vasopressor (33.8%) compared with dopamine (56.4%, p<0.001), with no significant difference in hospital mortality (26.9% vs 31.9%, p=0.26).

Structured PICO

Does noradrenaline improve mortality and reduce arrhythmias compared to dopamine in patients with cardiogenic shock?

P

Population

1,310 patients with cardiogenic shock analyzed across three studies to compare the efficacy and safety of noradrenaline versus dopamine.

I

Intervention

Noradrenaline

C

Comparator

Dopamine

O

Outcome

Mortality and incidence of arrhythmiashard clinical

This review supports current guidelines recommending noradrenaline over dopamine as the first-line vasopressor in cardiogenic shock due to improved survival and a better safety profile regarding arrhythmias.

Limitations

Limited number of available randomized controlled trials specifically addressing cardiogenic shock
Included studies differ in patient populations, shock severity, and dosing protocols
Potential patient overlap between studies included in the meta-analysis
Retrospective study designs are inherently subject to selection bias and confounding factors
Limited number of randomized controlled trials specifically addressing cardiogenic shock
Differences in patient populations, shock severity, and dosing protocols among included studies
Inclusion of retrospective study designs subject to selection bias and confounding factors

Implication

Reinforces guideline preference for noradrenaline in cardiogenic shock; extends meta-analytic support for lower arrhythmia risk.

Abstract

Introduction and purpose: Cardiogenic shock is a clinically specific cause of death that is hard to treat, and choosing the most effective medication remains a major clinical challenge. The aim of this study is to provide key information about this clinical condition and to compare the drugs most frequently used in the treatment of cardiogenic shock: noradrenaline and dopamine. Materials and methods: A literature search was conducted using the medical database PubMed and Google Scholar. Articles were retrieved using the keywords: ,,Noradrenaline”, ,,Dopamine”, ,,Cardiogenic shock”, ,,Hypotension” in appropriate configuration. Results: Four studies were found with relevant topics. One of these studies was excluded due to different vasopressors being compared in one of the trials considered in the meta-analysis. Finally, 3 scientific articles were systematically analyzed in our work. Conclusions: According to the available medical literature, recommendations, and guidelines, the use of noradrenaline in patients with cardiogenic shock is usually the most appropriate choice. However, the choice of dopamine is also available but it has been linked with a higher risk of complications linked with cardiac arrhythmias.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liebert et al. (2026) conducted a review in Cardiogenic shock (n=1,310). Noradrenaline vs. Dopamine was evaluated. Noradrenaline is associated with better safety and clinical outcomes compared with dopamine in patients with cardiogenic shock, particularly with a lower risk of arrhythmic complications.

synapsesocial.com/papers/6ac19d70aeea5716e8c6c67c https://doi.org/10.31435/ijitss.3(51).2026.4927

View Full Paper

Ask AI

Bookmark

Share

Noradrenaline or Dopamine in Cardiogenic Shock - A Literature Review

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Noradrenaline or Dopamine in Cardiogenic Shock - A Literature Review

Key Points

Structured PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading